Louis Onghena
- ORCID iD
-
0000-0002-8516-4834
Show
Sort by
-
- Journal Article
- A1
- open access
PPARĪ±-ERRĪ± crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression
-
- Journal Article
- A1
- open access
The pan-PPAR agonist lanifibranor reduces portal pressure independent of fibrosis reduction through the splanchnic vasculature
-
Bariatric surgery is a major independent factor of disease progression in cirrhotic patients with alcohol-related liver disease
-
The double-edged sword of bariatric surgery : extending the excluded limb can trigger bacterial translocation, liver inflammation and death
-
Transgenerational maternal obesity induces mitochondrial dysfunction and aggravates MASLD, which can be reversed by metabolic drug candidates
-
Evolution of health-related quality of life in liver transplantation patients in relation to acceptance and metabolic liver disease
-
- Journal Article
- A1
- open access
Prior metabolic and bariatric surgery is an independent determinant of severity of decompensation in alcohol-associated liver disease
-
Novel bariatric surgery models in mice-differential effects on body weight loss and fatty liver disease
-
The pan-PPAR agonist lanifibranor decreases portal pressure in models of both hepatic and prehepatic portal hypertension
-
Patients hospitalized with alcohol-related liver disease and prior bariatric surgery are more prone to develop acute-on-chronic liver failure